Cellular & Tissue Expression Profile: Ubiquitously expressed across tissues but functionally dominant in skeletal muscle (where PPARD is 10- to 50-fold more abundant than PPARA or PPARG), cardiac myocytes, brown and white adipose tissue, hepatic sinusoidal cells, and intestinal crypt stem cells.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Heterodimerizes with RXRA on PPREs: in unliganded basal muscle PPARD binds the corepressor BCL6, whereas upon exercise-induced fatty acid influx and PGC-1alpha (PPARGC1A) coactivation it releases BCL6 (which suppresses macrophage inflammation) and activates a comprehensive slow-twitch oxidative genetic program—inducing CPT1B, PDK4 (which inhibits pyruvate dehydrogenase to spare glucose for the brain and prevent hypoglycemic "hitting the wall"), UCP2/UCP3, VEGFA angiogenesis, and slow myosin heavy chain I fibers.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Landmark studies by Ronald Evans demonstrated that skeletal-muscle-specific constitutively active VP16-PPARD ("marathon mice") converts glycolytic type II fibers into mitochondria-rich type I oxidative fibers, confers resistance to high-fat-diet obesity, and nearly doubles continuous running distance even without prior training; human PPARD polymorphisms (such as +294T>C / rs2016520) are associated with HDL-cholesterol levels and aerobic training responsiveness.
Therapeutic & Clinical Pharmacology: While early high-potency synthetic agonist GW501516 (cardarine) was abandoned due to rodent gastrointestinal carcinogenicity at supraphysiological doses (and banned by WADA as a gene-doping agent), the selective oral PPAR-delta agonist seladelpar (Livdelzi) achieved FDA approval in 2024 for primary biliary cholangitis (PBC) by suppressing bile acid synthesis (CYP7A1) and cholestatic pruritus.